×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ACRS – aclaris therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ACRS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
07:24 pm
acrs
Aclaris Therapeutics And 2 Other US Penny Stocks To Watch [Yahoo! Finance]
Low
Report
Aclaris Therapeutics And 2 Other US Penny Stocks To Watch [Yahoo! Finance]
11/20
03:46 pm
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating.
Low
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating.
11/20
06:05 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
High
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
11/19
03:31 pm
acrs
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments [Yahoo! Finance]
Medium
Report
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments [Yahoo! Finance]
11/19
10:51 am
acrs
ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs [Yahoo! Finance]
High
Report
ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs [Yahoo! Finance]
11/19
08:29 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $7.00 price target on the stock, up previously from $2.00.
High
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $7.00 price target on the stock, up previously from $2.00.
11/19
07:30 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $7.00 price target on the stock, up previously from $2.00.
High
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $7.00 price target on the stock, up previously from $2.00.
11/19
07:30 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $8.00 price target on the stock.
High
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $8.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2024
07:00 am
ACRS
aclaris therapeutics, inc.
MISS
Report
7.6%
aclaris therapeutics, inc.
8/7/2024
07:00 am
ACRS
aclaris therapeutics, inc.
BEAT
Report
-2.5%
aclaris therapeutics, inc.
5/7/2024
04:01 pm
ACRS
aclaris therapeutics, inc.
BEAT
Report
-9.0%
aclaris therapeutics, inc.
2/27/2024
07:00 am
ACRS
aclaris therapeutics, inc.
BEAT
Report
-4.0%
aclaris therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/21
04:52 pm
acrs
Form SC 13G Aclaris Therapeutics, Filed by: Vivo Opportunity Fund Holdings, L.P.
Low
Report
Form SC 13G Aclaris Therapeutics, Filed by: Vivo Opportunity Fund Holdings, L.P.
11/20
04:20 pm
acrs
Form 4 Aclaris Therapeutics, For: Nov 19 Filed by: Mehra Anand
Medium
Report
Form 4 Aclaris Therapeutics, For: Nov 19 Filed by: Mehra Anand
11/18
04:21 pm
acrs
Form 3 Aclaris Therapeutics, For: Nov 18 Filed by: Davis Hugh M.
High
Report
Form 3 Aclaris Therapeutics, For: Nov 18 Filed by: Davis Hugh M.
11/18
08:16 am
acrs
Form 8-K Aclaris Therapeutics, For: Nov 16
High
Report
Form 8-K Aclaris Therapeutics, For: Nov 16
11/14
04:15 pm
acrs
Form SC 13G/A Aclaris Therapeutics, Filed by: CITADEL ADVISORS LLC
Medium
Report
Form SC 13G/A Aclaris Therapeutics, Filed by: CITADEL ADVISORS LLC
11/6
04:31 pm
acrs
Form 10-Q Aclaris Therapeutics, For: Sep 30
Medium
Report
Form 10-Q Aclaris Therapeutics, For: Sep 30
11/6
07:21 am
acrs
Form 8-K Aclaris Therapeutics, For: Nov 06
Medium
Report
Form 8-K Aclaris Therapeutics, For: Nov 06
11/5
04:20 pm
acrs
Form 4 Aclaris Therapeutics, For: Nov 01 Filed by: Walker Neal
Medium
Report
Form 4 Aclaris Therapeutics, For: Nov 01 Filed by: Walker Neal
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/16
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)
63.6%
11/7 Form 8-K Aclaris Therapeutics, For: Nov 07 39.3%
10/10 Aclaris Therapeutics Announces Divestiture of RHOFADE® 19.3%
1/9 Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor 17.2%
10/15 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.1%
7/9 Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1% 9.1%
12/19 Form SC 13D/A Aclaris Therapeutics, Filed by: Arkin Moshe 8.8%
9/5 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.6%
10/31 Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019 8.0%
2/10 Form SC 13G/A Aclaris Therapeutics, Filed by: Man Group plc 7.9%
11/7 Form 8-K Aclaris Therapeutics, For: Nov 07 39.3%
10/10 Aclaris Therapeutics Announces Divestiture of RHOFADE® 19.3%
1/9 Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor 17.2%
10/15 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.1%
7/9 Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1% 9.1%
12/19 Form SC 13D/A Aclaris Therapeutics, Filed by: Arkin Moshe 8.8%
9/5 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.6%
10/31 Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019 8.0%
2/10 Form SC 13G/A Aclaris Therapeutics, Filed by: Man Group plc 7.9%
TOP News Decliners
6/26
Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints
-52.1%
7/30 Glancy Prongay & Murray LLP Files Securities Class Action on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) -39.0%
2/25 Form 10-K Aclaris Therapeutics, For: Dec 31 -22.2%
8/8 Form 10-Q Aclaris Therapeutics, For: Jun 30 -13.5%
9/25 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm -11.7%
11/21 Form 8-K Aclaris Therapeutics, For: Nov 21 -11.2%
3/31 Form 8-K Aclaris Therapeutics, For: Mar 30 -11.1%
9/17 Aclaris Therapeutics to Hold R&D Day -10.9%
3/6 Form SC 13G Aclaris Therapeutics, Filed by: Samsara BioCapital, L.P. -10.8%
5/8 Form 10-Q Aclaris Therapeutics, For: Mar 31 -10.0%
7/30 Glancy Prongay & Murray LLP Files Securities Class Action on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) -39.0%
2/25 Form 10-K Aclaris Therapeutics, For: Dec 31 -22.2%
8/8 Form 10-Q Aclaris Therapeutics, For: Jun 30 -13.5%
9/25 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm -11.7%
11/21 Form 8-K Aclaris Therapeutics, For: Nov 21 -11.2%
3/31 Form 8-K Aclaris Therapeutics, For: Mar 30 -11.1%
9/17 Aclaris Therapeutics to Hold R&D Day -10.9%
3/6 Form SC 13G Aclaris Therapeutics, Filed by: Samsara BioCapital, L.P. -10.8%
5/8 Form 10-Q Aclaris Therapeutics, For: Mar 31 -10.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: